Michael Korn has joined Biocartis NV as its Chief Medical and Scientific Officer
Michael Korn shared a post on LinkedIn:
“With great excitement, I have joined Biocartis NV, an innovative molecular diagnostics company, as its Chief Medical and Scientific Officer.
In line with my passion for precision oncology, Biocartis‘ decentralized approach allows for delivering critically crucial molecular test results within hours at the point of care. The platform is also ideally suited for incorporating integral biomarkers in clinical trials.
I look forward to working with the Biocartis team and collaboration partners in academia and biopharma to provide rapid, clinically relevant molecular testing to cancer patients worldwide.”
Source: Michael Korn/LinkedIn
Michael Korn is the Chief Medical and Scientific Officer at Biocartis NV. He is also a professor at the University of California, San Francisco. His research primarily involves systems biology and computational models to understand signal transduction in cancer.
He focuses on designing combination therapies targeting receptor tyrosine kinase signaling and key pathways such as MAPK and PI3K.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023